At a glance
ClinicalIndex Comparison Record- ✓Aged 18-75 years
- ✓Pathologically confirmed lung, liver, pancreas or retroperitoneal malignant tumor
- ✓Oligometastasis in metastatic tumor
- ✓Tumor ≥2cm or distance to organs at risk <5mm
- ✕Prior radiotherapy for the lesion
- ✕History of malignancy within 5 years
- ✕ECOG ≥2
- ✕Significant abnormality in blood routine, liver/kidney function, or coagulation tests
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
NCT06427460Phase 2RecruitingUpdate OverdueUpdated 25mo ago · Completion was 12mo agoCentral-boost Ablative Radiation Therapy for Large Tumors or Tumors Adjacent to Organs at Risk
In Brief
A Phase 2 clinical trial evaluating Central-boost ablative dose delivered by stereotactic body radiation therapy for Pancreatic Cancer. Currently recruiting, targeting 67 participants across 1 site.
Signals
Detailed Summary
In the case of large tumors or tumors closely adjacent to organs at risk, ablative doses offered by stereotactic body radiation therapy (SBRT) could not be delivered. Therefore, a technique that could provide high radiation doses to tumors without increasing of risks of severe adverse effects is required.
Study Details
Timeline
Interventions
An inner and complete gross tumor volume (iGTV) is created within the gross tumor volume (GTV). For the liver or lung tumor, the convetional radiation dose is 35-45Gy/5f. Regarding the pancreatic tumor or retroperitoneal tumor, the radiation dose is 30-40Gy/5f. Hence, the radiation dose of iGTV should not be less than 120% of the dose of GTV.